Vir Biotechnology Inc (VIR)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -521,960 | -533,344 | -483,040 | -539,437 | -615,117 | -600,747 | -262,022 | -143,740 | 515,837 | 1,142,694 | 1,077,810 | 1,216,116 | 528,584 | -102,319 | -297,356 | -390,336 | -298,665 | -256,787 | -220,492 | -223,253 |
| Total stockholders’ equity | US$ in thousands | 1,150,380 | 1,240,730 | 1,433,670 | 1,547,360 | 1,590,240 | 1,675,080 | 1,810,210 | 1,970,760 | 2,077,960 | 2,149,860 | 1,952,010 | 2,001,010 | 1,431,850 | 876,274 | 737,325 | 650,951 | 716,852 | 812,355 | 563,779 | 380,333 |
| ROE | -45.37% | -42.99% | -33.69% | -34.86% | -38.68% | -35.86% | -14.47% | -7.29% | 24.82% | 53.15% | 55.22% | 60.78% | 36.92% | -11.68% | -40.33% | -59.96% | -41.66% | -31.61% | -39.11% | -58.70% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-521,960K ÷ $1,150,380K
= -45.37%
The return on equity (ROE) for Vir Biotechnology Inc has shown significant fluctuations over the analyzed period.
From March 2020 to June 2022, the ROE was consistently negative, indicating that the company was generating net losses in relation to its shareholders' equity during those periods. This could be a concerning sign for investors, as it suggests the company was not effectively utilizing its equity to generate profits.
However, the ROE saw a notable improvement in the latter part of 2022, with positive ROE figures recorded in December 2021, March 2022, and June 2022. During this period, the company demonstrated an ability to generate profits from its equity, which could be seen as a positive development for its financial health and performance.
Subsequently, the ROE experienced fluctuations, turning negative again in the following quarters from March 2023 to December 2024. These negative values suggest that the company's profitability in relation to its equity had deteriorated once more, potentially indicating challenges in generating returns for its shareholders.
Overall, the ROE trend for Vir Biotechnology Inc indicates a mix of positive and negative performance in terms of generating returns from shareholders' equity. Investors may want to further investigate the reasons behind these fluctuations to better understand the company's financial performance and prospects.
Peer comparison
Dec 31, 2024